{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:02:15Z","timestamp":1775041335092,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:00:00Z","timestamp":1609113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Neutralizing antibodies are a major correlate of protection for many viruses including the novel coronavirus SARS-CoV-2. Thus, vaccine candidates should potently induce neutralizing antibodies to render effective protection from infection. A variety of in vitro assays for the detection of SARS-CoV-2 neutralizing antibodies has been described. However, validation of the different assays against each other is important to allow comparison of different studies. Here, we compared four different SARS-CoV-2 neutralization assays using the same set of patient samples. Two assays used replication competent SARS-CoV-2, a focus forming assay and a TCID50-based assay, while the other two assays used replication defective lentiviral or vesicular stomatitis virus (VSV)-based particles pseudotyped with SARS-CoV-2 spike. All assays were robust and produced highly reproducible neutralization titers. Titers of neutralizing antibodies correlated well between the different assays and with the titers of SARS-CoV-2 S-protein binding antibodies detected in an ELISA. Our study showed that commonly used SARS-CoV-2 neutralization assays are robust and that results obtained with different assays are comparable.<\/jats:p>","DOI":"10.3390\/vaccines9010013","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T20:03:03Z","timestamp":1609185783000},"page":"13","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Comparison of Four SARS-CoV-2 Neutralization Assays"],"prefix":"10.3390","volume":"9","author":[{"given":"Lydia","family":"Riepler","sequence":"first","affiliation":[{"name":"Department of Hygiene, Microbiology and Public Health, Institute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5298-0288","authenticated-orcid":false,"given":"Annika","family":"R\u00f6ssler","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Microbiology and Public Health, Institute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Falch","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Microbiology and Public Health, Institute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Volland","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Microbiology and Public Health, Institute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8011-5825","authenticated-orcid":false,"given":"Wegene","family":"Borena","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Microbiology and Public Health, Institute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"von Laer","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Microbiology and Public Health, Institute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5210-7905","authenticated-orcid":false,"given":"Janine","family":"Kimpel","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Microbiology and Public Health, Institute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,28]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2020, December 22). WHO Coronavirus Disease (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int."},{"key":"ref_2","unstructured":"FIND (2020, December 22). SARS-CoV-2 Diagnostic Pipeline. Available online: https:\/\/www.finddx.org\/covid-19\/pipeline\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.cmi.2020.06.024","article-title":"Validation of a commercially available SARS-CoV-2 serological immunoassay","volume":"26","author":"Meyer","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"eabc3103","DOI":"10.1126\/scitranslmed.abc3103","article-title":"A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations","volume":"12","author":"Grzelak","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1099\/jgv.0.001439","article-title":"The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection","volume":"101","author":"Kellam","year":"2020","journal-title":"J. Gen. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gupta, V., Bhoyar, R.C., Jain, A., Srivastava, S., Upadhayay, R., Imran, M., Jolly, B., Divakar, M.K., Sharma, D., and Sehgal, P. (2020). Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2. Clin. Infect. Dis.","DOI":"10.31219\/osf.io\/4fmrg"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"To, K.K., Hung, I.F., Ip, J.D., Chu, A.W., Chan, W.M., Tam, A.R., Fong, C.H., Yuan, S., Tsoi, H.W., and Ng, A.C. (2020). COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis.","DOI":"10.1093\/cid\/ciaa1275"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Peterhoff, D., Gluck, V., Vogel, M., Schuster, P., Schutz, A., Neubert, P., Albert, V., Frisch, S., Kiessling, M., and Pervan, P. (2020). A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. Infection.","DOI":"10.1007\/s15010-020-01503-7"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Knabl, L., Mitra, T., Kimpel, J., Roessler, A., Volland, A., Walser, A., Ulmer, H., Pipperger, L., Binder, S.C., and Riepler, L. (2020). High SARS-CoV-2 Seroprevalence in Children and Adults in the Austrian Ski Resort Ischgl. medRxiv.","DOI":"10.1101\/2020.08.20.20178533"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1002\/cpmc.108","article-title":"An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening","volume":"58","author":"Amanat","year":"2020","journal-title":"Curr. Protoc. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1084\/jem.20201181","article-title":"Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses","volume":"217","author":"Schmidt","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Crawford, K.H.D., Eguia, R., Dingens, A.S., Loes, A.N., Malone, K.D., Wolf, C.R., Chu, H.Y., Tortorici, M.A., Veesler, D., and Murphy, M. (2020). Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses, 12.","DOI":"10.1101\/2020.04.20.051219"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zettl, F., Meister, T.L., Vollmer, T., Fischer, B., Steinmann, J., Krawczyk, A., V\u2019Kovski, P., Todt, D., Steinmann, E., and Pfaender, S. (2020). Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. Vaccines, 8.","DOI":"10.3390\/vaccines8030386"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","article-title":"A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells","volume":"78","author":"Hoffmann","year":"2020","journal-title":"Mol. Cell."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1128\/JVI.00666-08","article-title":"Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46","volume":"83","author":"Hermann","year":"2009","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1099\/vir.0.023978-0","article-title":"Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity","volume":"91","author":"Hoffmann","year":"2010","journal-title":"J. Gen. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1128\/JVI.03276-13","article-title":"VSV-GP: A potent viral vaccine vector that boosts the immune response upon repeated applications","volume":"88","author":"Tober","year":"2014","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1128\/JVI.78.17.9007-9015.2004","article-title":"Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein","volume":"78","author":"Giroglou","year":"2004","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.virusres.2011.06.029","article-title":"Characterization of the spike protein of human coronavirus NL63 in receptor binding and pseudotype virus entry","volume":"160","author":"Lin","year":"2011","journal-title":"Virus Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Ojha","year":"2020","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e61312","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"eLife"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/1\/13\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:46:47Z","timestamp":1760179607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/1\/13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["vaccines9010013"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9010013","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,28]]}}}